Combination Treatment With Plasmapheresis and Rituximab for Recurrent Focal Segmental Glomerulosclerosis After Renal Transplantation
Authors:
- 19 April 2011
- journal article
- case report
- Published by Wiley in Artificial Organs
- Vol. 35 (4) , 420-425
Abstract
Therapy for recurrent focal segmental glomerulosclerosis (FSGS) in the renal allograft is largely based on case reports. The use of plasmapheresis alone (based on its effectiveness in children) appears less effective in adults, reaching a response rate of <40%. Recently, rituximab, an anti‐CD20 monoclonal chimeric antibody, showed promising results as rescue therapy in plasmapheresis‐resistant recurrent FSGS. However, following rituximab administration, response is variable, often slow and consequently overlooked. We report a series of four cases of recurrent FSGS following renal transplantation successfully treated with a combination of plasmapheresis and rituximab. Complete remission of proteinuria occurred in two and partial remission in the other two patients whereas renal function improved or remained stable. During treatment and the follow‐up period (18–60 months) no severe infectious complications were observed. Our data suggest that the combination of plasmapheresis and rituximab is an acceptable treatment in patients with post‐transplantation recurrent FSGS.Keywords
This publication has 22 references indexed in Scilit:
- Intensive and Prolonged Treatment of Focal and Segmental Glomerulosclerosis Recurrence in Adult Kidney Transplant Recipients: A Pilot StudyAmerican Journal of Transplantation, 2009
- Rituximab treatment of idiopathic membranous nephropathyKidney International, 2008
- Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosisTransplant International, 2007
- Rituximab for refractory focal segmental glomerulosclerosisPediatric Nephrology, 2007
- Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosisTransplant International, 2007
- Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?Pediatric Nephrology, 2007
- Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximabTransplant International, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005
- Recurrence of glomerulonephritis following renal transplantationNephrology Dialysis Transplantation, 1999